The independent medical news service

Click through to find out more

Click through for the details of these evidence-based recommendations

An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.

More information about this Clinical Practice Guideline available here

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

Use of veliparib during cisplatin chemotherapy may help improve progression-free survival in patients with metastatic triple-negative breast cancer displaying biomarker characteristics similar to those seen in BRCA1/2 mutation-positive disease, suggest findings from a phase 2 trial.

The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

A phase 2 trial has demonstrated the promising efficacy and tolerability of neoadjuvant gemcitabine plus split-dose cisplatin in patients with localised high-grade upper tract urothelial carcinoma.

Find out more about the evidence-based recommendations here

Lorlatinib offers a “durable benefit” for the first-line treatment of advanced ALK-positive non-small-cell lung cancer, indicates a 3-year update from the CROWN trial.

A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.

A pooled analysis of clinical trial data points to a link between obesity and an increased risk for any-grade immune-related adverse events among people receiving nivolumab monotherapy for advanced cancer.

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

Children with a new diagnosis of acute lymphoblastic leukaemia who receive intensified central nervous system-directed therapy have an increased risk of neurocognitive deficits, indicates research published in the Journal of Clinical Oncology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Men with advanced prostate cancer may derive a significant survival benefit from the concurrent use of statins alongside androgen-ablative therapies, suggest the Canadian authors of a systematic review and meta-analysis.

Study findings reported in Rheumatology suggest that anti-SSSCA1 antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis.